Literature DB >> 29947262

In vitro effects of some antibiotics on glucose-6-phosphate dehydrogenase from rat (Rattus norvegicus) erythrocyte.

Yusuf Temel1, Adnan Ayna2, Ibrahim Hamdi Shafeeq2, Mehmet Ciftci2.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) plays a key function in various biochemical processes as they produce reducing power of the cell. Thus, metabolic reprogramming of nicotinamide adenine dinucleotide homeostasis is reported to be an important step in cancer progression as well as in combinational therapeutic approaches. In this study, the effects of the antibiotics, furosemide, cefazolin, cefuroxime, gentamicin and clindamycin on rat erythrocyte G6PD enzyme was studied in in vitro conditions. The enzyme was purified by 2', 5'-adenosine diphosphate Sepharose 4B affinity chromatography in a single purification step with 1825 fold and 83.7% yield. The specific activity of the enzyme was 29.2 EU/mg proteins. The inhibition studies of these antibiotics were carried out on the enzyme revealing that gentamicin, clindamycin and furosemide inhibited the activity of the G6PD with an IC50 of 1.75, 34.65 and 0.526 mM, respectively with Ki of 0.7, 39.8 and 0.860 mM, respectively. All inhibition types were analyzed by Lineweaver-Burk diagram showing noncompetitive inhibition for furosemide and gentamicin while clindamycin inhibited the activity competitively. On the other hand, cefazolin and cefuroxime increased the activity of the enzyme.

Entities:  

Keywords:  Antibiotics; G6PD; enzyme; furosemide; gentamicin; inhibition

Year:  2018        PMID: 29947262     DOI: 10.1080/01480545.2018.1481083

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  1 in total

1.  The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.

Authors:  Onur Argan; Kübra Çıkrıkçı; Aybike Baltacı; Nahit Gencer
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.